Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Financial Times: Analysts say Pfizer moving too slow on M&A

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Mar 04, 2023 1:27pm

190 Views

Post# 35319330

RE:Financial Times: Analysts say Pfizer moving too slow on M&A

Meanwhile in February 2023 Roche had been occupied with the purchase of a block of voting shares from a member of the controlling family shareholding group – heirs of Roche founder Fritz Hoffmann-La Roche – which was sold part of their stake in the accelerated book build run by UBS.

With the completion of this voting share repurchase it would appear that Roche now has more time to focus on its external M&A activities.

https://www.pharmalive.com/roche-buys-back-shares-as-family-group-reduces-voting-stake-in-drugmaker/

<< Previous

Bullboard Posts

Next >>

From now on, dynaCERT instead of Bitcoin or NVIDIA?